Prime Highlights
- Ipsen will acquire Kartos Therapeutics for $450 million to strengthen its oncology pipeline with late-stage therapy navtemadlin.
- The deal includes up to $1.3 billion in milestone payments, highlighting strong commercial potential.
Key Facts
- Navtemadlin is in Phase III trials for myelofibrosis, with data expected in 2027 and a potential launch in 2028.
- Ipsen expects the acquisition to contribute to core operating income from 2029, subject to regulatory approval and deal closure.
Background
French biotech company Ipsen has agreed to acquire US-based Kartos Therapeutics for $450 million, adding a late-stage blood cancer treatment to its oncology pipeline.
The deal hands Ipsen navtemadlin, an investigational oral therapy currently in a Phase III clinical trial for myelofibrosis, a rare and serious blood cancer. Kartos shareholders stand to receive up to $1.3 billion in additional payments tied to regulatory approvals and sales milestones.
Initial trial data is expected in 2027. If results go well, Ipsen could launch the therapy as early as 2028, giving the company a potential new revenue stream in a disease area with limited treatment options.
Ipsen said the acquisition will start contributing to core operating income from 2029. The deal is expected to close before the end of the third quarter of this year, pending antitrust clearance.
The purchase marks a significant step in Ipsen’s push to grow its oncology business. Myelofibrosis scars the bone marrow, blocking normal blood cell production. Approved treatments for the disease remain limited, pushing patients and drugmakers to seek better options.
Navtemadlin targets a specific protein pathway tied to cancer cell survival. Its oral format is a practical advantage over infusion or injection-based therapies, giving patients a simpler way to manage treatment over time.
The Kartos deal gives Ipsen a late-stage asset that cuts down the early development risk that usually comes with building an oncology pipeline from scratch.
